Paracentesis is the standard treatment for refractory ascites in patients with cirrhosis, but it cannot prevent the recurrence of ascites. The placement of a transjugular intrahepatic portosystemic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In a retrospective cohort study, ...
A new low-flow ascites pump significantly reduced paracentesis frequency in patients with a contraindication to transjugular intrahepatic portosystemic shunt, or TIPS, according to a recently ...
The Ascites may be due to cancer like ovarian malignancy. Cirrhosis of liver is the most common cause and the underlying liver disease is to be addressed first. The patient has to be counselled to ...
HERNIA is known to be more frequent among patients with cirrhosis of the liver, especially with ascites, than among those without liver disease. Chapman et al. 1 reported a rate of 10 per cent in 58 ...
Rising prevalence of cirrhosis is a major factor boosting the growth of the global malignant ascites market. According to a study published in the World Journal of Gastroenterology in 2011, over 50% ...
Background: A 63-year-old Caucasian woman presented with intermittent, left-sided abdominal discomfort without other symptoms. Physical examination revealed massive splenomegaly and complete blood ...
THE preparation of hemisulfur mustard, the rationale that led to discovery of its palliative properties and its effect after administration to patients with malignant tumors have been reported. § When ...
CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback